Earnings call transcript: Tilray Q3 2026 results show strong growth

Tilray reported Q3 FY2026 net revenue of $206.7M, up 11% YoY, adjusted EBITDA of $10.7M (+19% YoY) and ended the quarter with $264.8M in cash; net loss narrowed to $25.2M from $793.5M a year earlier (improvement of $768.3M). Management reaffirmed FY2026 adjusted EBITDA guidance of $62–$72M and projects FY revenue of ~$1.74B, while executing strategic beverage moves (BrewDog acquisition for ~GBP40M and a U.S. licensing partnership with Carlsberg) to drive scale. Near-term risks include regulatory uncertainty around hemp/Delta-9 and U.S. cannabis reform, price compression in Germany, and commodity/input cost pressure (e.g., aluminum), though the company cites hedges, Project Four Twenty cost savings and international supply expansion to mitigate headwinds.

Analysis

Tilray’s integration play—combining brewing scale with a regulated cannabis platform and a European pharma distribution asset—creates an unusually diversified optionality profile that investors often underweight. The beverage side provides immediate procurement leverage (cans, hops, logistics) that can compress COGS across the enlarged footprint; model a 200–700 bps gross-margin tailwind for beverage within 12–24 months if procurement contracts and route-to-market rationalization proceed as management expects.

CC Pharma’s distribution asset is the most underappreciated structural moat: vertical access into pharmacies and doctor channels converts supply-side strength into durable price/volume negotiating power in European medical cannabis markets. The practical result is less sensitivity to pure wholesale price competition and more control over unit economics—stress-test scenarios should assume distribution-driven margin expansion in Europe over a 2–3 year horizon.

Primary macro/regulatory risk is a binary U.S. hemp/Delta‑9 outcome and continued European price compression; either can lurch revenue mix quickly. Investors should differentiate short-term seasonality/working-capital noise from structural EPS inflection: if management delivers quarter-to-quarter margin recovery in beverage plus stable pharma distribution monetization, the path to sustained profitability becomes credible within 12–18 months.

The biggest behavioral mispricing: the market prices Tilray more like a single-industry cannabis LP than a multi‑vertical consumer+pharma+beverage operator. That compresses upside relative to the execution risk profile—if integration milestones (procurement synergies, pharmacy penetration, BrewPub stabilization) hit on schedule, a re-rating could be swift given current liquidity and M&A optionality.

Key Decisions for Investors

• TLRY — Tactical long with hedge: Accumulate 1–2% NAV TLRY equity on multi‑week weakness and buy a 12‑month protective put (30–40% OTM) or a 12–18 month bull call spread (buy 25–40% OTM call, sell 60–80% OTM call). Rationale: asymmetric upside from procurement and pharma synergies; hedge limits regulatory binary downside. Timeframe: 6–18 months. Risk/Reward: pay <=2% premium for puts or limited debit for spread; target 40–100% upside if integration executes.
• TLRY options — Event volatility play: Buy an 3–6 month strangle (OTM puts and calls) sized for <0.5% NAV ahead of key catalysts (Q4 results, Carlsberg rollout milestones, European pharmacy rollouts). Rationale: monetize jump in implied volatility around binary news (integration updates, regulatory guidance). Risk/Reward: limited premium paid vs potential >2x payoff on realized move.
• Pair trade — Long TLRY / Short HITI (or comparable single‑category beverage/energy peer): 1.5:1 notional long TLRY vs short HITI to express beverage consolidation & distribution scale thesis while hedging sector cyclicality. Timeframe: 6–12 months. Risk/Reward: if TLRY captures procurement leverage and HITI faces growth/margin pressure, expect relative outperformance of 20–50%; downside if sector rebound is broad-based.
• Risk hedge — Short-tail insurance: Buy deep OTM puts on TLRY or sell covered calls on a portion of position after a strong run — size 0.5–1% NAV. Rationale: blunt regulatory ban or severe European price shock which could remove a chunk of hemp/beverage revenue quickly. Timeframe: horizon through next major regulatory milestones (up to Nov 2026). Risk/Reward: small known cost for protection against low-probability, high-impact downside.